Biophytis SA (ALBPS) AI Stock Analysis

Biophytis SA

(Paris:ALBPS)

Select Model

Rating:42Neutral

Price Target:EUR 0.06▲(116.49% Upside)

Action:reiterated

Date:01/30/26

The score is primarily constrained by weak financial fundamentals—no revenue, ongoing losses, negative equity, and continued cash burn despite 2024 improvement. Technicals add modest downside bias with bearish MACD and the stock below key longer-term moving averages, while valuation offers limited insight because earnings are negative and there is no dividend yield support.

Positive Factors

Focused clinical-stage specializationSpecialization in age-related diseases and muscle-function therapeutics indicates a focused R&D strategy and domain expertise. A concentrated pipeline can create differentiated assets, streamline trial design and partner appeal, supporting durable value creation if clinical progress continues.

Negative Factors

No revenue over multiple yearsAbsence of product revenue across multiple years means the company lacks operating cash generation and remains fully reliant on financing or partners. This structural revenue gap increases execution risk and constrains long-term sustainability until commercialization or licensing occurs.

Biophytis SA (ALBPS) vs. iShares MSCI France ETF (EWQ)

Market Cap: EUR 11.52M
Dividend Yield: ―
Average Volume (3M): 35.69M
Price to Earnings (P/E): -0.0
Beta (1Y): 1.27
Revenue Growth: ―
EPS Growth: 90.97%
Country: France
Employees: 20
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Biophytis SA Business Overview & Revenue Model

Company Description

Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying...

How the Company Makes Money

Biophytis SA is a clinical-stage company and, as such, does not have recurring revenue from marketed products; its operations are primarily funded through external financing rather than product sales. The company’s potential ways of generating revenu...

Biophytis SA Financial Statement Overview

Summary

Development-stage profile with no revenue (2020–2024) and persistent losses. While losses and cash burn improved meaningfully in 2024, the balance sheet is highly stressed with deeply negative equity and ongoing funding/dilution risk.

Income Statement

8Very Negative

Balance Sheet

6Very Negative

Cash Flow

12Very Negative

Financial statement breakdown
Breakdown	TTM	Jun 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	-298.00K	-298.00K	-803.00K	-484.00K	-311.00K	-280.00K
EBITDA	-8.20M	-8.20M	-13.53M	-25.52M	-26.50M	-13.66M
Net Income	-10.38M	-10.38M	-17.03M	-24.22M	-31.16M	-25.52M
Balance Sheet
Total Assets	6.90M	6.90M	11.96M	21.99M	36.26M	27.21M
Cash, Cash Equivalents and Short-Term Investments	78.00K	78.00K	5.57M	11.05M	25.16M	18.35M
Total Debt	9.84M	9.84M	8.27M	14.58M	17.55M	9.10M
Total Liabilities	16.60M	16.60M	15.85M	23.90M	30.56M	20.38M
Stockholders Equity	-9.67M	-9.67M	-3.86M	-1.88M	5.83M	2.30M
Cash Flow
Free Cash Flow	-8,643	-8.64M	-13.09M	-19.13M	-24.14M	-10.08M
Operating Cash Flow	-8,643	-8.64M	-12.87M	-18.99M	-23.80M	-9.86M
Investing Cash Flow	10.00K	10.00K	370.00K	-17.00K	12.16M	-12.71M
Financing Cash Flow	3.65M	3.14M	7.03M	6.13M	29.71M	21.95M

Biophytis SA Technical Analysis

Technical Analysis SentimentNegative

Last Price0.03

Price Trends

50DMA0.05Negative

100DMA0.04Negative

200DMA0.04Negative

Market Momentum

MACD-0.01Positive

RSI33.06Neutral

STOCH44.26Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALBPS, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.05, and below the 200-day MA of 0.04, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 33.06 is Neutral, neither overbought nor oversold. The STOCH value of 44.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALBPS.

Biophytis SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

FR:ALBPS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:POXEL	46Neutral	EUR 8.87M	-0.43	33.88%	―	―	―
FR:ABVX	44Neutral	EUR 6.92B	-16.78	-85.88%	―	―	―
FR:ALNEV	43Neutral	EUR 173.61K	0.00	-26.52%	―	-44.46%	100.00%
FR:ALBPS	42Neutral	EUR 11.52M	-0.01	153.48%	―	―	90.97%
FR:AELIS	38Underperform	EUR 9.91M	-2.19	―	―	-97.09%	45.00%
FR:ALVAL	37Underperform	EUR 22.31M	-2.13	-87.66%	―	183.47%	57.15%

* Healthcare Sector Average

Performance Comparison

FR:ALBPS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
FR:ALBPS	Biophytis SA	0.03	-0.08	-71.70%
FR:ABVX	Abivax SA	79.05	-4.25	-5.10%
FR:POXEL	Poxel SA	0.17	-0.17	-50.30%
FR:ALVAL	Valbiotis SA	0.63	-0.01	-0.95%
FR:ALNEV	Neovacs SA	0.10	-375.90	-99.97%
FR:AELIS	Aelis Farma SA	0.72	-0.41	-36.02%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jan 30, 2026

Biophytis SA AI Stock Analysis